Pharmacy Department update

June 23, 2021  //  FOUND IN: Strategy & Leadership

Over the past few years, the Pharmacy Department has made exceptional strides to optimize both operations and partnerships across the clinical enterprise.

Chief Pharmacy Officer Stan Kent has provided extraordinary leadership, guiding the department to make significant improvements in controlled substance management, DEA compliance, compounding capabilities, drug distribution services in patient care areas and critical daily operations. Chief Medical Officer Jeff Desmond, M.D., has also provided guidance and leadership of Pharmacy Department activities and enhancements over the past few years.

Since last year, the Strategy Department has been working with pharmacy leadership and many other stakeholders to evaluate opportunities to further expand services, including Specialty Pharmacy, to support the future needs of the community.

To better position the department for this future growth, pharmacy will transition from the Office of the Chief Medical Officer to the U-M Health President’s office, effective July 1.

“This transition will enable resource allocation and decision-making that support more rapid growth efforts, and further strengthen our organization’s ability to support our pharmacists, clinicians and our growing patient populations,” said David Miller, M.D., M.P.H., president of U-M Health.

A new role, interim chief operating officer for pharmacy, will be created to focus on and support the operations, accelerate business development and drive clinical partnership strategies that will enable sustained operational excellence alongside expanded service models and growth.

Based on her operational experience and long-standing leadership roles in health care, Dana Habers, who joined Michigan Medicine in 2016 as chief department administrator for Radiology, has been appointed to serve in this role for the next 6-12 months.

After Habers’ transition, radiology plans to post the CDA position and recruit for a replacement.  

With this new structure, Kent, the chief pharmacy officer, will continue to direct and strengthen daily operations and clinical programs, and will report directly to Habers, effective July 6. At this point, this is an interim structure and continued assessment of the department is needed to determine the permanent, long-term structure and reporting relationships.